Comparison of the effects of sitagliptin and dapagliflozin on time in range in Japanese patients with type 2 diabetes stratified by body mass index: A sub‐analysis of the DIVERSITY‐CVR study
Authors' conclusion
In Japanese patients with early-stage type 2 diabetes, sitagliptin was associated with improved TIR in patients with a lower BMI. Dapagliflozin was effective in patients with a higher BMI.
Study context
- Population
- Japanese patients with early-stage T2D, stratified by baseline characteristics including body mass index (BMI)
- Participants
- 340 patients
- Comparison
- Sitagliptin vs dapagliflozin
- Primary endpoint
- Achievement rate of time in range (TIR) >70% and of HbA1c <7.0% by baseline BMI subgroup (parent study primary endpoint: HbA1c <7.0%, body weight loss ≥3.0% and avoidance of hypoglycaemia)
- Follow-up
- 24 weeks
Methodological detailsprospective, randomized, multicentre, subgroup analysis stratified by baseline characteristics
- Prospective
- Randomized
- Multicentre
- Subgroup analysis stratified by baseline characteristics
Primary result
As reported in the abstract
TIR >70% by BMI subgroup
- Sitagliptin vs Dapagliflozin: P < 0.05
- Dapagliflozin vs Sitagliptin: P < 0.01
Further findings
| Outcome | P value |
|---|---|
| HbA1c <7.0% achievement, lower BMI subgroup71.1% vs 43.6%, higher with sitagliptin | P < 0.05 |
HbA1c <7.0% achievement, lower BMI subgroup
- No significant differences in other subgroups
Original publication
Comparison of the effects of sitagliptin and dapagliflozin on time in range in Japanese patients with type 2 diabetes stratified by body mass index: A sub‐analysis of the DIVERSITY‐CVR study. Diabetes Obes Metab. Published 8 May 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →